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Abstract
Background: While modulation of the serotonin transporter (5HTT) has shown to be a risk
factor for pulmonary arterial hypertension for almost 40 years, there is a lack of in vivo data about
the broad molecular effects of pulmonary inhibition of 5HTT. Previous studies have suggested
effects on inflammation, proliferation, and vasoconstriction. The goal of this study was to determine
which of these were supported by alterations in gene expression in serotonin transporter
knockout mice.
Methods:  Eight week old normoxic mice with a 5-HTT knock-out (5HTT-/-) and their
heterozygote(5HTT+/-) or wild-type(5HTT+/+) littermates had right ventricular systolic
pressure(RVSP) assessed, lungs collected for RNA, pooled, and used in duplicate in Affymetrix
array analysis. Representative genes were confirmed by quantitative RT-PCR and western blot.
Results: RVSP was normal in all groups. Only 124 genes were reliably changed between 5HTT-/-
and 5HTT+/+ mice. More than half of these were either involved in inflammatory response or
muscle function and organization; in addition, some matrix, heme oxygenase, developmental, and
energy metabolism genes showed altered expression. Quantitative RT-PCR for examples from
each major group confirmed changes seen by array, with an intermediate level in 5HTT +/- mice.
Conclusion: These results for the first time show the in vivo effects of 5HTT knockout in lungs,
and show that many of the downstream mechanisms suggested by cell culture and ex vivo
experiments are also operational in vivo. This suggests that the effect of 5HTT on pulmonary
vascular function arises from its impact on several systems, including vasoreactivity, proliferation,
and immune function.
Background
Idiopathic pulmonary arterial hypertension (IPAH) is a
disease characterized by pulmonary vasoconstriction,
inflammation, and vascular remodeling, whose early
events and molecular etiology are still obscure. Defects in
serotonin (5-HT) signaling have long been associated
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with idiopathic pulmonary arterial hypertension. From
1965 to 1972, the first appetite depressant-induced epi-
demic of pulmonary hypertension occurred in Europe fol-
lowing the release of aminorex[1]. During the 1990's,
French researchers reported increased incidence of pul-
monary hypertension among a patient population that
was administered derivatives of the medication fenflu-
ramine[2]. Dexfenfluramine, which is the active enanti-
omer of fenfluramine and used to treat obesity in patients,
was considered to be the chief culprit behind the increase
in cases of pulmonary hypertension[2,3]. Dexfenflu-
ramine acts as a substrate for the serotonin transporter (5-
HTT), causing increased extracellular 5-HT by a mecha-
nism involving exchange of drug molecules for intracellu-
lar 5-HT[4]. Dexfenfluramine also causes overexpression
of 5-HTT, but with the net effect of increased available 5-
HT[3,5].
Attenuation of hypoxic PAH in experimental mice can
occur pharmacologically through the administration of
dexfenfluramine[3]. Since increased 5-HT potentiates the
development of PAH in rodents[6] and likely in
humans[7], the simplest explanation for these data is
through direct effect on signaling through 5-HTT, rather
than by impact on 5-HT itself. Mice with a specific gene
knock-out for 5-HTT (5-HTT-/-) are also somewhat pro-
tected against hypoxic pulmonary hypertension[8,9], with
slightly lower right ventricular systolic pressure (RVSP) in
response to chronic hypoxia.
Transgenic mice overexpressing 5-HTT in smooth mus-
cle[10] or under its own promoter[9] spontaneously
develop PAH, although the mechanism is still unclear.
While 5-HTT is overexpressed in hypoxia, the rate of 5-HT
uptake has been reported as reduced.
There are several plausible mechanisms by which the loss
of 5HTT could protect against hypoxic PAH. Serotonin is
a mitogen, and can act as a smooth muscle mitogen
through 5-HTT[11]. Loss of 5-HTT might thus protect
against PASMC proliferation. Another potential mecha-
nism lies in the well-characterized impact of 5-HT on
smooth muscle tone, through receptor signaling[12,13]
and inhibition of K-channels[14]. 5HTT-/- mice have sub-
stantially lowered circulating 5-HT[8], and by analogy to
5HTT-/- rats likely plasma 5-HT[15], which should result
in decreased 5-HT-derived tone and thus protection
against IPAH. Finally, 5-HT modulates cytokine networks
in the lung[16], including in a feedback loop with inter-
leukin-1β and p38 MAPK[17].
The 5-HT pathway thus impacts several systems with rele-
vance to IPAH, including proliferation, tone, and inflam-
mation. The goal of this study was to examine changes in
gene expression in 5-HTT-/- mouse lung, to determine in
vivo which of the potential pathways was the likely molec-
ular source of their protection against PAH. We conducted
the study in normoxic mice, which lack phenotype, in
order to isolate the effects of the serotonin transporter
knockout in the absence of confounding factors caused by
hypoxia or increased pulmonary pressures.
Methods
Animals
5HTT-/- mice were constructed as previously described[8].
Wild-type, 5-HTT heterozygote or knockout mice were
allowed to reach adulthood at ambient pressure in Den-
ver, Colorado (85 KPa; ambient pressure at sea level is 100
KPa). The breeding colony was maintained as 5HTT+/-
(heterozygote), so all mice used were littermates. Mice
were genotyped by polymerase chain reaction using prim-
ers specific to the wild-type allele (ATATCCAATGGG-
TACTCCGCAG and TGGTGAATCTCAGCCACCAG) and
the neomycin resistance gene used in the knock-out
(TCGACGTTGTCACTGAAGCG and GGATACTTTCTCG-
GCAGGAGC).
Eight week old mice were anesthetized with ketamine 200
mg/kg and xylazine 10 mg/kg, the right jugular surgically
exposed. Right ventricular (RV) pressure was measured
using a 1.4 French Pressure Volume Conductance System
SPR-839 (Millar Instruments, Houston, Texas), which was
inserted into the RV through the surgically exposed right
jugular vein. The hemodynamic phenotyping results were
continuously recorded using a Millar MPVS-300 unit cou-
pled to a Powerlab 8-SP A/D converter, acquired at 1000
Hz. All hemodynamic phenotyping results were captured
to a Macintosh G4 computer utilizing Chart5.3 software.
Heparin was injected into the circulation prior to sacrifice,
the left atria removed, lungs flushed through the right
ventricle, and lungs collected and flash frozen in liquid
nitrogen. All animal studies were approved by the UCHSC
intramural animal care and use committee.
Affymetrix arrays
All RNA for the gene arrays consisted of sex-matched
pooled samples from three different animals, to reduce
variability, with two Mouse Genome 430 2.0 arrays used
for each condition (a total of six arrays from 18 pooled
animals are thus reported). Samples were prepared for
Affymetrix arrays using 2.5 μg of total lung RNA according
to the Affymetrix GeneChip Expression Analysis Manual.
All array results have been submitted to the NCBI gene
expression and hybridization array data repository (GEO,
http://www.ncbi.nlm.nih.gov/geo/), as series GSE11035.
Affymetrix cel files were imported into dChip [18], nor-
malized to median overall signal intensity, and the perfect
match/mismatch model used to determine per-gene
hybridization strength. Pairwise comparisons between
5HTT wildtype and knockout mouse arrays were used to
determine changed genes, with same-direction changes inBMC Pulmonary Medicine 2009, 9:19 http://www.biomedcentral.com/1471-2466/9/19
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all four pairwise comparisons needed for a gene to be con-
sidered changed. Gene ontology was determined using
the Classify Genes tool within dChip[18], with gene
ontology files downloaded from the Gene Ontology Con-
sortium http://www.geneontology.org[19].
Analysis focused on gene ontology groups rather than
highly changed individual genes for several reasons. First,
different strains can use different genes to accomplish the
same phenotypic end[20]; pathways are thus more impor-
tant than individual genes. Next, arrays are actually rather
poor at determining quantitative changes, as shown by
results in this study. Finally, our goal was to determine
overall pathways altered by loss of 5HTT, rather than indi-
vidual genes; selection of a low required fold change while
maintaining a low false-discovery rate is optimal for this
process.
Western blots
Western blots were performed as previously
described[21], using Klf4 rabbit polyclonal (1:500 dilu-
tion, CeMines, Golden, CO) and Kcne4 mouse mono-
clonal (1:300 dilution, Jackson ImmunoResearch
Laboratories, West Grove PA). Equal protein loading was
determined by Bradford assay; blots were stripped and
reprobed with antibodies to β-actin to confirm this. A sin-
gle strong band at the appropriate size was assumed to
indicate specificity.
Quantitative RT-PCR
Primers were designed using sequences downloaded from
Genbank with the Applied Biosystems ABI Primer Express
program(AB, Foster City, CA). Each primer was searched
against BLAST to ensure that it did not match any known
gene aside from that for which it was designed (especially
other family members). Upon receipt, each primer was
tested and titered to ensure it gave a single, clean band of
the appropriate size. Primer sequences are listed in Addi-
tional File 1. RNA was made from snap-frozen whole
mouse lung using a Qiagen RNeasy mini kit (Valencia,
CA), and first strand cDNA was created from 1 μg total
RNA using a Qiagen QuantiTect® Reverse Transcription Kit
(Valencia, CA). Quantitative RT-PCR was carried out
using SYBR Green chemistry in a 7300 Real Time PCR Sys-
tem (Applied Biosystems, Foster City, CA). Each measure-
ment was made in triplicate and expressed relative to the
detection of the housekeeping gene hypoxanthine gua-
nine phosphoribosyl transferase (HPRT). Absence of con-
taminating genomic DNA was confirmed by PCR of no-RT
control with cogenomic HPRT primers.
Results
5-HTT-/- mice have normal RVSP
While 5HTT-/- mice had never previously been found to
have abnormal RVSP, we wished to verify this before pro-
ceeding. Mice at 8 weeks of age were weighed and anesthe-
tized in preparation of closed-chested catheterization.
Right ventricular systolic pressure (RSVP) and heart rate
for each experimental mouse was obtained by inserting a
catheter into the right ventricle through a surgically
exposed right jugular vein. Under normoxic conditions,
with ambient pressure and spontaneous ventilation, RVSP
and heart rate were unchanged between 5-HTT+/+, 5-HTT+/
- and 5-HTT-/- mice (not shown).
5-HTT-/- mouse lungs have alterations in multiple 
pathways with relevance to PAH
RNA was extracted from homogenized whole lung from 5-
HTT+/+, 5-HTT+/-  and 5-HTT-/- mice, with RNA pooled
from 3 samples to reduce individual variability for each
chip. Two chips, with pools from different animals, were
used for wild-type, heterozygote, and homozygote 5-HTT
knockouts; all animals were littermates. RNA was used to
probe Affymetrix MOE430 v2 arrays. Affymetrix Cel files
were further analyzed with dChip.
Using relatively low stringency for comparisons, includ-
ing a minimum 1.2× fold change between any pair of
samples with a minimum threshold for absolute change
between any pair, we found 124 genes changed between
from 5-HTT+/+ and 5-HTT-/- mice with a false discovery rate
of 7%. Using the same criteria and swapping samples
between groups reduced this to 6–10 genes, indicating
that a large majority of the 124 genes likely represented
genotype-dependent changes. These were sorted into gene
ontology groups by dChip.
Half of these genes fell into one of two broad gene ontol-
ogy groups; stress response and immune related genes,
and genes related to muscle structure, vasoreactivity, or
actin dynamics (Figure 1, Additional File 2). Other catego-
ries included cell cycle and apoptosis, developmental,
energy metabolism, heme-oxygenes (HO-1), and matrix
related genes (Additional file 3). Where a gene fell into
more than one ontology group, for the purpose of these
tables it was placed in the group for which references
seemed to predominate. Changes in 5-HTT+/- mice by
array were similar to those in 5-HTT-/- mice (Additional
files 2, 3). Absolute changes shown are in arbitrary units
of hybridization intensity.
Quantitative RT-PCR shows dose effect and greater 
changes than arrays
To confirm results obtained by Affymetrix arrays, selected
genes from different categories were analyzed by quantita-
tive RT-PCR against cDNA derived from six individual
mice per group. These included inflammation-related
genes C/ebpβ and Il1β(Figure 2A), matrix related genes
Mmp9 and S100a8 (Figure 2B), muscle related genes Klf4
and Kcne4, and the developmental gene Klf9 (Figure 2C).BMC Pulmonary Medicine 2009, 9:19 http://www.biomedcentral.com/1471-2466/9/19
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We found in each case that quantitative RT-PCR con-
firmed the change seen on the Affymetrix arrays, with two
important differences (Additional file 4 and 5). First, in
most cases the fold change was much greater by quantita-
tive RT-PCR than by array, and second, there was an evi-
dent dose effect in six of seven genes by quantitative RT-
PCR which was not apparent by array.
Western blot confirms decreased protein expression of 
Klf4 and Kcne4
While most of the quantitative PCR results had very strong
statistical values, scatter in values was greater and the cor-
responding statistical significance weaker for muscle
developmental gene Klf4 and the voltage gated potassium
channel Kcne4. Western blot analysis was therefore per-
formed to confirm changes in protein level of these genes,
with comparison to β-actin for protein loading. We found
even protein loading with decreased Klf4 and Kcne4 pro-
tein across samples (Figure 3), with average decreases in
protein levels of 3.5× and 2.0× for Klf4 and Kcne4 respec-
tively by densitometry.
Discussion
There has been a long association between serotonin sig-
naling and pulmonary arterial hypertension[1], with
many mechanisms proposed for its effect, including
impact on vascular tone[12,13], proliferation, and
inflammation[16]. The goal of this study was to deter-
mine which of these mechanisms was plausible in vivo by
examining the gene expression consequences in homoge-
nized whole lung of serotonin transporter (5HTT) knock-
out and heterozygosity as compared to wild-type mice.
We found that pathways related to all of the proposed
mechanisms are altered in 5-HTT knockout mice. This is
the first report of broad in vivo consequences in lung of
loss of the serotonin transporter. We found a relatively
limited number of genes consistently changed, including
stress response, actin organization, cell cycle, energy
metabolism, heme oxygenase, matrix, and developmental
genes (Fig 1, Additional files 2, 3). Representative genes
from major groups were assayed by quantitative RT-PCR,
confirming their change, and showing intermediate levels
of change in 5HTT heterozygote mice (Fig 2). Genes with
weak p-values by quantitative RT-PCR were also con-
firmed by densitometry and western blot (Fig 3).
We were surprised that by gene array 5HTT heterozygote
mice seemed closer to the 5HTT knockouts than to the
wild-type mice, as it appears that haploinsufficiency in
5HTT does not alter 5 HT uptake, at least in brain[22].
However, the simplest interpretation of this is that altera-
tions in gene expression are the result of 5HTT function
directly, rather than secondary to 5 HT level. There are
multiple examples in the literature showing a dose-effect,
in which 5HTT heterozygotes have a phenotype midway
between knockouts and wild-type mice, in MDMA
response[22], platelet aggregation[23], and serotonin
receptor density in areas of the brain[24].
Expression analysis on brains of 5HTT knockout mice has
recently been performed[25]. Hippocampus with 5HTT
knockout also shows relatively few differentially regulated
genes (only 30), but with only one gene in common,
S100A9. There are a few additional genes with related
function: for example, in brain period homolog 2 (Per2)
has altered expression, while in lung it is Per1. However,
for the most part the gene lists do not overlap either in
pathway or in specific gene. This likely indicates very dif-
ferent signaling consequences of loss of 5HTT in brain
and lung.
The classes of genes discovered as dysregulated are partic-
ularly interesting because they are similar to classes of
genes found dysregulated in two mouse models which
develop PAH, including mice expressing a BMPR2 muta-
tion and mice with a vasoactive intestinal peptide (VIP)
knockout. BMPR2 is the gene mutated in most familial
PAH; adult mice expressing smooth-muscle specific muta-
tions in BMPR2 develop PAH, although with a phenotype
somewhat dependent on the mutation used[26,27]. VIP
knockout mice develop moderate PAH, including smooth
muscle proliferation and perivascular inflamma-
tion[28,29].
Distribution of ontology groups of 124 genes differentially  regulated in 5HTT-/- mouse whole lung as compared to litter- mate controls Figure 1
Distribution of ontology groups of 124 genes differen-
tially regulated in 5HTT-/- mouse whole lung as com-
pared to littermate controls.BMC Pulmonary Medicine 2009, 9:19 http://www.biomedcentral.com/1471-2466/9/19
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Quantitative RT-PCR confirmation of array changes for selected genes Figure 2
Quantitative RT-PCR confirmation of array changes for selected genes. Each point corresponds to RNA from an 
individual mouse. All changes are significant by ANOVA as p < .01 except Klf4 and Kcne4 which are significant at p < .05. 
Expression in 5HTT-/- is significantly different than expression in 5HTT+/+ for all genes at p < .05 by Tukey's Post Hoc.BMC Pulmonary Medicine 2009, 9:19 http://www.biomedcentral.com/1471-2466/9/19
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5HTT-/- mice, which are protected against hypoxic PAH,
show broad decreases in immune response genes (Addi-
tional file 2), while both VIP-/- and BMPR2 mutant mice
show increases in immune response gene expres-
sion[26,28,30]. Both VIP-/- and BMPR2 mutant mice show
increases in collagen, and BMPR2 mice show increased
matrix metalloproteinase(MMP) and matrix-related gene
S100A8; 5HTT-/- mice have decreased MMP and S100A8.
5HTT-/- mice have cell cycle changes that tend towards
lower proliferation, such as an increase in the cell cycle
inhibitor Fabp3 and a decrease in oncogene Fosl2(Addi-
tional file 3); VIP-/- and BMPR2 mutant mice have changes
trending towards an increase in proliferation. 5HTT-/-
mice have changes in vasoreactivity related genes which
suggest increased tone, including increases in muscle
structural genes and decreases in potassium channels
(Additional file 2). This is similar to although less pro-
nounced than trends seen in both VIP-/-  and BMPR2
mutant mice; one would not expect this to be protective.
Conclusion
The goal of this study was to examine changes in gene
expression in 5-HTT-/- mouse lung, to determine in vivo
which of the potential pathways was the likely molecular
source of their protection against PAH. We found that all
of the potential pathways, including proliferation, inflam-
mation, and vasoconstriction, among others, were altered.
However, of these only alterations in proliferation and
inflammation seem likely to underlie a protective effect of
loss of 5-HTT.
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Western blot analysis shows decreased protein expression  of Klf4 and Kcne4 in protein lysates from whole lungs of  5HTT-/- mice compared to controls; βactin demonstrates  even protein loading, and was present at approximately 45  kD Figure 3
Western blot analysis shows decreased protein 
expression of Klf4 and Kcne4 in protein lysates from 
whole lungs of 5HTT-/- mice compared to controls; 
βactin demonstrates even protein loading, and was 
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